Regeneron advocates industry-FDA collaboration to establish regulatory standards for novel applications of genomic data, such as determining whether long-term outcomes studies are needed, and inclusion of the data in product labeling.

AstraZeneca has entered into a series of early research collaborations in a bid to integrate genomics into the foundations of its entire drug discovery and development infrastructure.

A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.